Nuveen LLC Buys New Shares in Nuvation Bio Inc. $NUVB

Nuveen LLC bought a new stake in Nuvation Bio Inc. (NYSE:NUVB - Free Report) during the 1st quarter, according to its most recent Form 13F filing with the SEC. The firm bought 453,792 shares of the company's stock, valued at approximately $799,000. Nuveen LLC owned 0.13% of Nuvation Bio as of its most recent SEC filing.

Other hedge funds have also recently bought and sold shares of the company. Wealth Enhancement Advisory Services LLC acquired a new stake in shares of Nuvation Bio in the 4th quarter valued at approximately $27,000. Forum Financial Management LP acquired a new stake in shares of Nuvation Bio in the 4th quarter valued at approximately $29,000. Firethorn Wealth Partners LLC acquired a new stake in shares of Nuvation Bio in the 1st quarter valued at approximately $35,000. BNP Paribas Financial Markets acquired a new stake in shares of Nuvation Bio in the 4th quarter valued at approximately $64,000. Finally, Aquatic Capital Management LLC acquired a new stake in shares of Nuvation Bio in the 4th quarter valued at approximately $84,000. 61.67% of the stock is owned by institutional investors.

Analysts Set New Price Targets

NUVB has been the topic of a number of research analyst reports. Wedbush restated an "outperform" rating and issued a $5.00 price target on shares of Nuvation Bio in a research note on Wednesday, June 11th. JMP Securities restated a "market outperform" rating and issued a $6.00 price target on shares of Nuvation Bio in a research note on Wednesday, June 25th. Wall Street Zen upgraded shares of Nuvation Bio from a "sell" rating to a "hold" rating in a research note on Sunday, August 17th. Finally, Royal Bank Of Canada lifted their target price on shares of Nuvation Bio from $6.00 to $7.00 and gave the stock an "outperform" rating in a research report on Friday, August 8th. One research analyst has rated the stock with a Strong Buy rating and five have issued a Buy rating to the company's stock. According to data from MarketBeat, the stock currently has an average rating of "Buy" and an average target price of $7.33.

Nuvation Bio Trading Up 13.5%

Shares of NYSE NUVB traded up $0.46 during midday trading on Friday, reaching $3.88. The stock had a trading volume of 21,993,749 shares, compared to its average volume of 5,051,995. The firm has a market cap of $1.33 billion, a price-to-earnings ratio of -6.16 and a beta of 1.36. Nuvation Bio Inc. has a twelve month low of $1.54 and a twelve month high of $4.09. The company has a debt-to-equity ratio of 0.13, a quick ratio of 9.38 and a current ratio of 9.39. The company's 50 day moving average price is $2.52 and its 200 day moving average price is $2.21.

Nuvation Bio (NYSE:NUVB - Get Free Report) last issued its quarterly earnings results on Thursday, August 7th. The company reported ($0.17) earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of ($0.17). The firm had revenue of $4.83 million for the quarter, compared to the consensus estimate of $0.42 million. Nuvation Bio had a negative net margin of 1,413.43% and a negative return on equity of 46.14%. As a group, sell-side analysts expect that Nuvation Bio Inc. will post -0.36 EPS for the current year.

Nuvation Bio Profile

Nuvation Bio Inc, a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-868, a BD2 selective oral small molecule BET inhibitor that epigenetically regulates proteins that control tumor growth and differentiation, including oncogenes comprising c-myc; NUV-1156, an AR binder Xtandi that address advanced stage prostate cancers with the potential to move into earlier lines typically treated with surgical prostatectomy; and drug-drug conjugate (DDC) platform which leverages a novel therapeutic approach within the drug-conjugate class of anti-cancer therapies to deliver anti-cancer therapeutics to cancer cells, as well as NUV-1176, a PARP inhibitor to address ER+ breast and ovarian cancer.